{
    "ticker": "GTX",
    "name": "GTx, Inc.",
    "description": "GTx, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for patients with cancer and other serious medical conditions. Founded in 2000, GTx specializes in the discovery and development of selective androgen receptor modulators (SARMs) and other compounds with the potential to improve the treatment landscape for patients. The company is particularly known for its work in hormone therapies, targeting conditions such as prostate cancer and muscle wasting associated with cancer and other diseases. GTx's lead product candidate, enobosarm, has shown promise in clinical trials for treating androgen deficiency and muscle wasting, positioning the company as a pivotal player in addressing unmet medical needs within oncology and related areas. GTx is committed to advancing its innovative therapies through rigorous clinical research and collaborations, aiming to deliver meaningful improvements in patient outcomes. The company\u2019s mission is to enhance the lives of patients by providing access to effective, targeted treatments that address their specific health challenges, while striving to lead the way in biopharmaceutical innovation.",
    "industry": [
        "Biopharmaceuticals",
        "Oncology"
    ],
    "headquarters": "Memphis, Tennessee, USA",
    "founded": "2000",
    "website": "http://www.gtxinc.com",
    "ceo": "Mitchell S. Steiner, M.D.",
    "social_media": {
        "twitter": "https://twitter.com/GTx_Inc",
        "linkedin": "https://www.linkedin.com/company/gtx-inc-/"
    },
    "investor_relations": "http://www.gtxinc.com/investor-relations",
    "key_executives": [
        {
            "name": "Mitchell S. Steiner, M.D.",
            "position": "CEO"
        },
        {
            "name": "Daniel W. G. S. Garber",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Enobosarm",
                "Selective Androgen Receptor Modulators"
            ]
        }
    ],
    "seo": {
        "meta_title": "GTx, Inc. | Innovative Biopharmaceuticals for Oncology",
        "meta_description": "Explore GTx, Inc., a biopharmaceutical company specializing in innovative therapeutics for cancer and serious medical conditions. Learn about GTx's mission and product development.",
        "keywords": [
            "GTx",
            "Biopharmaceuticals",
            "Cancer Treatments",
            "Selective Androgen Receptor Modulators",
            "Enobosarm"
        ]
    },
    "faq": [
        {
            "question": "What does GTx specialize in?",
            "answer": "GTx specializes in the development of innovative therapeutics for cancer and other serious medical conditions."
        },
        {
            "question": "Who is the CEO of GTx?",
            "answer": "Mitchell S. Steiner, M.D. is the CEO of GTx, Inc."
        },
        {
            "question": "Where is GTx headquartered?",
            "answer": "GTx is headquartered in Memphis, Tennessee, USA."
        },
        {
            "question": "What is GTx's lead product candidate?",
            "answer": "GTx's lead product candidate is enobosarm, which targets androgen deficiency and muscle wasting."
        },
        {
            "question": "When was GTx founded?",
            "answer": "GTx was founded in 2000."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "MRNA",
        "REGN"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "GOOGL",
        "AMZN"
    ]
}